164 related articles for article (PubMed ID: 37558938)
1. Developing a Kinase Chemogenomic Set: Facilitating Investigation into Kinase Biology by Linking Phenotypes to Targets.
Wells CI; Drewry DH
Methods Mol Biol; 2023; 2706():11-24. PubMed ID: 37558938
[TBL] [Abstract][Full Text] [Related]
2. Progress towards a public chemogenomic set for protein kinases and a call for contributions.
Drewry DH; Wells CI; Andrews DM; Angell R; Al-Ali H; Axtman AD; Capuzzi SJ; Elkins JM; Ettmayer P; Frederiksen M; Gileadi O; Gray N; Hooper A; Knapp S; Laufer S; Luecking U; Michaelides M; Müller S; Muratov E; Denny RA; Saikatendu KS; Treiber DK; Zuercher WJ; Willson TM
PLoS One; 2017; 12(8):e0181585. PubMed ID: 28767711
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of the Published Kinase Inhibitor Set.
Elkins JM; Fedele V; Szklarz M; Abdul Azeez KR; Salah E; Mikolajczyk J; Romanov S; Sepetov N; Huang XP; Roth BL; Al Haj Zen A; Fourches D; Muratov E; Tropsha A; Morris J; Teicher BA; Kunkel M; Polley E; Lackey KE; Atkinson FL; Overington JP; Bamborough P; Müller S; Price DJ; Willson TM; Drewry DH; Knapp S; Zuercher WJ
Nat Biotechnol; 2016 Jan; 34(1):95-103. PubMed ID: 26501955
[TBL] [Abstract][Full Text] [Related]
4. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome.
Martin E; Mukherjee P
J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092
[TBL] [Abstract][Full Text] [Related]
5. Predicting kinase inhibitors using bioactivity matrix derived informer sets.
Zhang H; Ericksen SS; Lee CP; Ananiev GE; Wlodarchak N; Yu P; Mitchell JC; Gitter A; Wright SJ; Hoffmann FM; Wildman SA; Newton MA
PLoS Comput Biol; 2019 Aug; 15(8):e1006813. PubMed ID: 31381559
[TBL] [Abstract][Full Text] [Related]
6. The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.
Wells CI; Al-Ali H; Andrews DM; Asquith CRM; Axtman AD; Dikic I; Ebner D; Ettmayer P; Fischer C; Frederiksen M; Futrell RE; Gray NS; Hatch SB; Knapp S; Lücking U; Michaelides M; Mills CE; Müller S; Owen D; Picado A; Saikatendu KS; Schröder M; Stolz A; Tellechea M; Turunen BJ; Vilar S; Wang J; Zuercher WJ; Willson TM; Drewry DH
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429995
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Data-Driven Assessment of Non-Kinase Targets of Inhibitors of the Human Kinome.
Mobasher M; Vogt M; Xerxa E; Bajorath J
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540679
[TBL] [Abstract][Full Text] [Related]
8. PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials.
Carles F; Bourg S; Meyer C; Bonnet P
Molecules; 2018 Apr; 23(4):. PubMed ID: 29662024
[TBL] [Abstract][Full Text] [Related]
9. Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors.
Xerxa E; Laufkötter O; Bajorath J
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570774
[TBL] [Abstract][Full Text] [Related]
10. PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor.
Tamir TY; Drewry DH; Wells C; Major MB; Axtman AD
Sci Rep; 2020 Sep; 10(1):15826. PubMed ID: 32985588
[TBL] [Abstract][Full Text] [Related]
11. System-based drug discovery within the human kinome.
Bamborough P
Expert Opin Drug Discov; 2012 Nov; 7(11):1053-70. PubMed ID: 22971083
[TBL] [Abstract][Full Text] [Related]
12. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets.
Vieth M; Higgs RE; Robertson DH; Shapiro M; Gragg EA; Hemmerle H
Biochim Biophys Acta; 2004 Mar; 1697(1-2):243-57. PubMed ID: 15023365
[TBL] [Abstract][Full Text] [Related]
13. An Introduction to Chemogenomics.
Chaikuad A; Merk D
Methods Mol Biol; 2023; 2706():1-10. PubMed ID: 37558937
[TBL] [Abstract][Full Text] [Related]
14. Integrated single-dose kinome profiling data is predictive of cancer cell line sensitivity to kinase inhibitors.
Joisa CU; Chen KA; Berginski ME; Golitz BT; Jenner MR; Herrera Loeza G; Yeh JJ; Gomez SM
PeerJ; 2023; 11():e16342. PubMed ID: 38025707
[TBL] [Abstract][Full Text] [Related]
15. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.
Yang X; Huang Y; Crowson M; Li J; Maitland ML; Lussier YA
J Biomed Inform; 2010 Jun; 43(3):376-84. PubMed ID: 20434586
[TBL] [Abstract][Full Text] [Related]
16. Data sets of human and mouse protein kinase inhibitors with curated activity data including covalent inhibitors.
Xerxa E; Bajorath J
Future Sci OA; 2023 Oct; 9(9):FSO892. PubMed ID: 37752915
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling.
Zhang L; Holmes IP; Hochgräfe F; Walker SR; Ali NA; Humphrey ES; Wu J; de Silva M; Kersten WJ; Connor T; Falk H; Allan L; Street IP; Bentley JD; Pilling PA; Monahan BJ; Peat TS; Daly RJ
J Proteome Res; 2013 Jul; 12(7):3104-16. PubMed ID: 23692254
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome.
Laufkötter O; Laufer S; Bajorath J
Data Brief; 2020 Oct; 32():106189. PubMed ID: 32904416
[TBL] [Abstract][Full Text] [Related]
19. Trends in kinase selectivity: insights for target class-focused library screening.
Posy SL; Hermsmeier MA; Vaccaro W; Ott KH; Todderud G; Lippy JS; Trainor GL; Loughney DA; Johnson SR
J Med Chem; 2011 Jan; 54(1):54-66. PubMed ID: 21128601
[TBL] [Abstract][Full Text] [Related]
20. Data-Driven Global Assessment of Protein Kinase Inhibitors with Emphasis on Covalent Compounds.
Xerxa E; Miljković F; Bajorath J
J Med Chem; 2023 Jun; 66(11):7657-7665. PubMed ID: 37212701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
